Qyuns Therapeutics Tightens Audit Committee Mandate to Bolster Governance

Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) has shared an update.

Qyuns Therapeutics has formalized detailed terms of reference for its board Audit Committee to enhance decision-making and oversight of financial reporting and internal control systems. The committee is mandated to review the company’s financial condition and data, assess the authenticity and accuracy of financial information, supervise communications with external auditors, and guide internal audit work to strengthen internal controls and risk management.

The document also sets structural requirements for the Audit Committee, which must comprise at least three non-executive directors, with a majority being independent non-executive directors and at least one member holding appropriate accounting or financial management qualifications in line with Hong Kong Listing Rules. The company commits to providing necessary resources and cooperation from management to ensure the committee can effectively execute its responsibilities, signaling a reinforced governance framework for investors and other stakeholders.

The most recent analyst rating on (HK:2509) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.

More about Qyuns Therapeutics Co., Ltd. Class H

Qyuns Therapeutics Co., Ltd. is a pharmaceutical company operating in the therapeutics sector and listed in Hong Kong. The company is governed under the Company Law of the People’s Republic of China and the Hong Kong Listing Rules, and it emphasizes robust financial reporting, internal controls, and audit oversight as part of its corporate governance framework.

Average Trading Volume: 241,118

Technical Sentiment Signal: Sell

Current Market Cap: HK$4.29B

For an in-depth examination of 2509 stock, go to TipRanks’ Overview page.